Core Insights - The company, Hongbo Pharmaceutical, has opened its DiOrion-GPT large model for trial use to select partners, receiving positive feedback overall [1] - The company is currently engaged in multiple functional optimizations and system upgrades, with an official update expected in the coming months [1] - By the end of 2024, the company's CADD/AIDD technology platform is projected to have supported a total of 80 new drug projects, with the number of clients purchasing CADD/AIDD services reaching 40 [1]

Core Insights - The company reported a revenue of 544 million yuan for 2024, representing a year-on-year growth of 11.18%, while the net profit attributable to shareholders decreased by 54.59% to 17.08 million yuan [1] - The company is a new drug research and development service provider, increasing its R&D investment, which amounted to 47.26 million yuan, accounting for 8.68% of total revenue [1] - The compound annual growth rate (CAGR) for revenue from 2022 to 2024 is 6.70%, while the CAGR for R&D expenses is significantly higher at 40.21% [1] R&D and Technical Platforms - As of the end of 2024, the company has delivered a total of 55 candidate drug molecules to clients, with 10 new additions compared to 2023, and 47 of these are First-in-Class (FIC) projects, making up 85.45% of the total [1] - The company has established 12 core technology platforms since 2019, including CADD/AIDD, enzyme chemistry, photochemistry, and others, to enhance its technological capabilities [1] Business Development - The CADD/AIDD technology platform has supported 80 new drug projects, with 6 entering clinical Phase I and 1 entering clinical Phase II, and the number of clients utilizing CADD/AIDD services has reached 40 [2] - The company has intensified its marketing and promotional efforts, participating in 19 domestic and international exhibitions and forums during the reporting period, leading to progress in active customer numbers and new order amounts [2] - The company provides comprehensive services for global pharmaceutical and biotechnology companies, focusing on drug discovery, pharmaceutical process development, and customized/commercial production of active pharmaceutical ingredients and key intermediates [2]